



Client: ACCESS MEDICAL LABORATORI 1	Patient: TEST, PATIENT
5151 CORPORATE WAY	Room# DOB. 04/05/1980 Age:39 Sex:M
JUPITER, FL 33458	Phone: () - Fasting: N
Phys: SARA, ALAN (561) 745-1233	ID#: A1908001649260
	Route#: 0 Page:1

Acc# 001649260	Coll. Date: 08/22/19	Recv. Date: 08/22/19	Print Date: 08/22/19
Chart#	Coll. Time: 00:00 AM	Recv. Time:04:04 PM	Print Time: 17:02
First reported on:	08/22/19	Final report date:	08/22/19

Test Name	Results	Reference Range	Units
-----------	---------	-----------------	-------

Report Status: FINAL

COMMENTS:

COMPLETE BLOOD COUNT

WHITE BLOOD CELL	10.0	3.9 - 11.1	K/ul
RED BLOOD CELL	5.25	4.20 - 6.00	M/ul
HEMOGLOBIN	15.0	13.2 - 18.0	g/dl
HEMATOCRIT	45.0	38.5 - 54.0	%
MCV	95	80.0 - 100.0	fl
MCH	30.0	26.0 - 34.0	pg
MCHC	33.0	31.0 - 37.0	g/dl
RDW	14.0	11.0 - 15.5	%
PLATELET COUNT	350	140 - 400	k/ul
MPV	10.0	7.5 - 11.6	fl

AUTOMATED DIFFERENTIAL

DIFFERENTIAL

Granulocyte %	55.0	38.0 - 75.0	%
Lymphocyte %	30.0	15.0 - 49.0	%
Monocyte %	1.0 L	2.0 - 13.0	%
Eosinophil %	3.0	0.0 - 8.0	%
Basophil %	2.0	0.0 - 2.0	%
Granulocyte #	5.5	1.6 - 8.4	K/ul
Lymphocyte #	3.0	1.0 - 3.6	K/ul
Monocyte #	0.1	0.0 - 0.9	K/ul
Eosinophil #	0.3	0.0 - 0.6	K/ul
Basophil #	0.2	0.0 - 0.2	K/ul

GENERAL CHEMISTRY

GLUCOSE	95	65 - 100	mg/dl
BUN	12.0	6 - 20	mg/dl
CREATININE, SERUM	2.5 H	0.7 - 1.3	mg/dl
SODIUM	140	136 - 145	mmol/L
POTASSIUM	5.0	3.5 - 5.1	mmol/L
CHLORIDE	106	100 - 110	mmol/L
CO2	25.0	20 - 31	mmol/L
CALCIUM	9.0	8.3 - 10.6	mg/dl
TOTAL PROTEIN	7.5	5.7 - 8.2	g/dl
ALBUMIN	3.5	3.2 - 4.8	g/dl
GLOBULIN	4.0 H	2.1 - 3.6	g/dl

(Continued on Next Page)



Client: ACCESS MEDICAL LABORATORI 1 5151 CORPORATE WAY JUPITER, FL 33458	Patient: TEST, PATIENT Room# DOB. 04/05/1980 Age:39 Sex:M Phone: () - Fasting: N ID#: A1908001649260 Route#: 0
Phys: SARA, ALAN (561) 745-1233	Page:2

Acc# 001649260	Coll. Date: 08/22/19	Recv. Date: 08/22/19	Print Date: 08/22/19
Chart#	Coll. Time: 00:00 AM	Recv. Time:04:04 PM	Print Time: 17:02
First reported on:	08/22/19	Final report date:	08/22/19

Test Name	Results	Reference Range	Units
-----------	---------	-----------------	-------

GENERAL CHEMISTRY (Continued)

BILIRUBIN, TOTAL	1.2	0.3 - 1.2	mg/dl
ALKALINE PHOSPHATASE	90	45 - 115	U/L
ALT	21	0 - 48	U/L
AST	25	0 - 38	U/L
Albumin/Globulin Ratio	0.9	0.8 - 2.0	
BUN/CREAT RATIO	N/A	7.3 - 21.7	
GFR, estimated	31		ml/min

If African-American, result is: 37

Calculation of estimated GFR is based on the MDRD Study prediction equation
 ****Five Stages of Chronic Kidney Disease****

Stage	*GFR Level*	*Description*
Stage 1	90 ml/min or more	Healthy Kidneys or Kidney damage with normal or high GFR
Stage 2	60 to 89 ml/min	Kidney damage and mild decrease in GFR
Stage 3	30 to 59 ml/min	Moderate decrease in GFR
Stage 4	15 to 29 ml/min	Severe decrease in GFR
Stage 5	< 15 ml/min	Kidney failure, or on dialysis

DIABETES EVALUATION

HEMOGLOBIN A1C	5.6	< 5.7	%
----------------	-----	-------	---

Diagnosis	***HbA1c Level***
Normal	< 5.7 %
Prediabetes	5.7 - 6.4 %
Diabetes	= or > 6.5 %

Having prediabetes is a Risk Factor for getting type 2 diabetes. Within the prediabetes range(5.7-6.4), the higher the HbA1c,the greater the risk of diabetes. HbA1c target for diabetics depend on their history and health.

IRON/ANEMIA EVALUATION

FERRITIN	20.0	10.5 - 307.3	ng/ml
----------	------	--------------	-------

CORONARY RISK

TRIGLYCERIDES	95	<150	mg/dl
CHOLESTEROL, TOTAL	150	<200	mg/dl
HDL CHOLESTEROL	60	>40	mg/dl
LDL CHOLESTEROL, calc.	71	<100	mg/dl
CHOL/HDL RATIO	2.5	<5.0	

(Continued on Next Page)

Client: ACCESS MEDICAL LABORATORI 1 5151 CORPORATE WAY JUPITER, FL 33458	Patient: TEST, PATIENT Room# DOB. 04/05/1980 Age:39 Sex:M Phone: () - Fasting: N ID#: A1908001649260 Route#: 0
Phys: SARA, ALAN (561) 745-1233	Page:3

Acc# 001649260	Coll. Date: 08/22/19	Recv. Date: 08/22/19	Print Date: 08/22/19
Chart#	Coll. Time: 00:00 AM	Recv. Time:04:04 PM	Print Time: 17:02
First reported on:	08/22/19	Final report date:	08/22/19

Test Name	Results	Reference Range	Units
-----------	---------	-----------------	-------

CORONARY RISK (Continued)

The higher the Ratio,the higher CHD risk.

CRP, Cardio	3.5 H	<3	mg/L
Risk of Cardiovascular Disease			
Low Risk		CRP < 1.0	mg/L
Medium Risk		CRP 1.0 - 3.0	mg/L
High Risk		CRP > 3.0	mg/L
Vitamin D,25-OH,Total	30.0	30 - 100	ng/ml

Notes:

Therapy is based on the measurement of Total Vitamin D (25-OH).
Most experts agree that Vitamin D deficiency should be = or < 20 ng/ml.
Vitamin D insufficiency is recognized as 21 - 29 ng/ml.
The preferred level for Vitamin D (25-OH)is recommended to be 30 - 100 ng/ml.
Vitamin D > 150 ng/ml is considered potentially toxic.

THYROID TESTING

T3, FREE	3.5	2.3 - 4.2	pg/ml
T4, FREE	1.7	0.89 - 1.76	ng/dl
TSH	5.0 H	0.550 - 4.780	uIU/ml

TUMOR MARKERS

PSA, TOTAL	3.5	0.000 - 4.000	ng/ml
------------	-----	---------------	-------

ENDOCRINE EVALUATION

FSH	5.0	1.4 - 18.1	mIU/ml
LH	5.0	1.5 - 9.3	mIU/ml
PROGESTERONE	3.3 H	0.28 - 1.22	ng/mL
ESTRONE (E1)	2.0	< 60	pg/ml.
ESTRADIOL (E2)	20.0	0.0 - 39.9	pg/mL
DHEA-SULFATE	100.0	34.5 - 568.9	ug/dl
DIHYDROTESTOSTERONE	3.5 L	11.2 - 95.5	ng/dL

(Continued on Next Page)



Client: ACCESS MEDICAL LABORATORI 1 5151 CORPORATE WAY JUPITER, FL 33458	Patient: TEST, PATIENT Room# _____ DOB. 04/05/1980 Age:39 Sex:M Phone: () - _____ Fasting: N ID#: A1908001649260 Route#: 0
Phys: SARA, ALAN (561) 745-1233	Page:4

Acc# 001649260	Coll. Date: 08/22/19	Recv. Date: 08/22/19	Print Date: 08/22/19
Chart#	Coll. Time: 00:00 AM	Recv. Time: 04:04 PM	Print Time: 17:02
First reported on: 08/22/19		Final report date: 08/22/19	

Test Name	Results	Reference Range	Units
-----------	---------	-----------------	-------

ENDOCRINE EVALUATION (Continued)

TESTOSTERONE, TOTAL	5.0 L	280 - 1100	ng/dl
SEX HORMONE BIND GLOBULIN	95.0	14 - 95	nmol/L
TESTOSTERONE, FREE	0.0 L	4.3 - 24.0	ng/dl
IGF-1	100 L	124 - 181	ng/mL

Access Medical Laboratories uses Siemens Healthcare Diagnostics as the supplier for IGF-1 Immunoassay Testing System. Siemens Introduced a Restandardization of IGF-1 assay using WHO 1st International Standard (IS), NIBSC Code 02/254.

Starting 01/25/2017 we will be implementing the new restandardized IGF-1 assay for testing Patients. New Reference Ranges will reflect expected lower values for patient IGF-1 results.

IGFBP-3	56.0 H	3.4 - 6.7	ug/ml
CORTISOL	20.0		ug/dl

****Normal individuals****

Morning am 7-9:	5.2 - 22.5 ug/dL
Afternoon pm 3-5 :	3.4 - 16.8 ug/dL

Lab Developed Testing

Serum Pregnenolone, DHT, Estrone, Estriol, 25-OH Vitamin D2 and D3 were developed and their performance characteristics determined by Access Medical Laboratories.

It has not been cleared or approved by the FDA.

The laboratory is regulated under CLIA and qualified to perform high-complexity testing. These tests are used for clinical purposes. It should not be regarded as investigational or for research.



Client: **ACCESS MEDICAL LABORATORI** 1
5151 CORPORATE WAY
JUPITER, FL 33458

Phys: SARA, ALAN (561) 745-1233

Patient: **TEST, PATIENT**
Room# DOB. 04/05/1980 Age:39 Sex:M
Phone: () - Fasting: N
ID#: A1908001649260
Route#: 0 Page:5

Acc# **001649260** Coll. Date: 08/22/19 Recv. Date: 08/22/19 Print Date: 08/22/19
Chart# Coll. Time: 00:00 AM Recv. Time:04:04 PM Print Time: 17:02
First reported on: 08/22/19 Final report date: 08/22/19

Test Name	Results	Reference Range	Units
-----------	---------	-----------------	-------

ENDOCRINE EVALUATION (Continued)

_____ **END OF REPORT** _____